Memotropil

Piracetam, the active ingredient in Memotropil, is a racetam presented as an intravenous solution for injection use. It is prescribed for cognitive impairment, dementia, myoclonus, and vertigo, primarily in adult patients requiring neuroprotective support and related neurological conditions.

GNH USA supplies Memotropil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established logistics for regulated markets. The company adheres to EU quality standards and provides batch‑specific documentation for regulatory compliance. Customers benefit from reliable supply chains and responsive technical support.

Piracetam is a racetam nootropic that influences cerebral metabolism and neuronal function.

Cognitive impairment: improves attention and memory performance in affected individuals. Dementia: supports cognitive function and may slow decline in patients with degenerative dementia. Myoclonus: reduces frequency and intensity of involuntary muscle jerks. Vertigo: alleviates dizziness by enhancing vestibular neuronal signaling.

Adverse reactions may occur with intravenous piracetam administration.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating sleep. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or anaphylaxis. - Injection site thrombophlebitis: pain, redness, or swelling. - Seizure exacerbation: increased seizure frequency. - Severe skin rash: Stevens‑Johnson‑type reactions. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: reduced clearance leading to toxicity.

Careful assessment is required before initiating therapy. - Renal function: adjust use in severe renal impairment. - Pregnancy: prescribe only if clearly needed after risk‑benefit evaluation. - Breastfeeding: consider potential exposure to the infant. - Elderly: monitor for confusion or worsening cognition. - Concomitant CNS depressants: use with caution due to additive sedation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed prior to therapy.

Major Interactions (Avoid): - Anticoagulants: increased risk of bleeding. - CNS depressants: enhanced sedation and respiratory depression. - Methotrexate: possible neurotoxic synergy.

Moderate Interactions (Monitor Closely): - Diuretics: may cause electrolyte disturbances. - Anticonvulsants: could alter seizure threshold. - Alcohol: may increase dizziness and CNS effects.